Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Irwin, N.
Right arrow Articles by Flatt, P. R
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Maximising the therapeutic potential of glucagon-like peptide-1 in type 2 diabetes

Nigel Irwin

School of Biomedical Sciences, University of Ulster, Coleraine, Northern Ireland, UK, n.irwin{at}ulster.ac.uk

Marc Moodley

Medical Department, Novartis Pharmaceuticals, Camberley, UK

Peter R Flatt

School of Biomedical Sciences, University of Ulster, Coleraine, Northern Ireland, UK

Tight control of blood glucose levels is fundamental for delaying or preventing the progression of metabolic complications in type 2 diabetes. Glucagon-like peptide-1 (GLP-1), secreted from the L-cells of the distal small intestine and colon in response to feeding, promotes insulin production and secretion, reduces glucagon secretion, delays gastric emptying and induces satiety. However, native GLP-1 is rapidly degraded by dipeptidyl peptidase (DPP) 4 reducing its therapeutic utility. Two approaches have been adopted to extend duration of action, namely enzyme-resistant GLP-1 mimetics and DPP 4 inhibitors which additionally promote insulin release by GIP. Clinical trials of incretin-based therapies have shown good efficacy in improving glycaemic control in type 2 diabetes. These therapies can be added to metformin or thiazolidinediones in order to target efects of insulin secretion as well as insulin action. However, incretin therapies also show potential when combined with approaches that increase insulin by endogenous (via sulphonylureas) or exogenous routes. Synergistic actions of incretin therapies with sulphonylureas on pancreatic beta-cells are also potentially advantageous. Incretin therapies can reduce hypoglycaemia since GLP-1 increases glucose sensing of both insulin and glucagon-secreting cells. Br J Diabetes Vasc Dis 2009; 9: 44—52

Key Words: DPP 4 inhibitor • exenatide • GIP • GLP-1 • glucagon-like peptide-1 • glucose-dependent insulinotropic polypeptide • liraglutide • sitagliptin • sulphonylureas • type 2 diabetes • vildagliptin

References

  • Bailey CJ, Day C. Glycaemic memory. Br J Diabetes Vasc Dis 2008; 5:242-7.
  • The UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Stratton IM, Adler AI, Neil HAW et al. on behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.[Abstract/Free Full Text]
  • Boulé NG, Haddad E., Kenny GP et al. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. J Am Med Assoc 2001;286:1218-27.[Abstract/Free Full Text]
  • Krentz AJ, Bailey CJ Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005;65:385-411.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ashcroft FM, Gribble FM ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia 1999;42:903-19.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bryan J., Crane A., Vila-Carriles WH, Babenko AP, Aguilar-Bryan L. Insulin secretagogues, sulfonylurea receptors and K(ATP) channels. Curr Pharm Des 2005;11:2699-716.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Flatt PR, Shibier O., Szecowka J., Berggren PO New perspectives on the actions of sulphonylureas and hyperglycaemic sulphonamides on the pancreatic beta-cell. Diabetes Metab 1994;20:157-62.[Web of Science]
  • Tian YA, Johnson G., Ashcroft SJ Sulfonylureas enhance exocytosis from pancreatic beta-cells by a mechanism that does not involve direct activation of protein kinase C. Diabetes 1998;47:1722-6.[Abstract]
  • Kamp F., Kizilbash N., Corkey BE, Berggren PO, Hamilton JA Sulfonylureas rapidly cross phospholipid bilayer membranes by a free-diffusion mechanism. Diabetes 2003;52:2526-31.[Abstract/Free Full Text]
  • World Health Organization. WHO Model List of Essential Medicines, March 2007, 15th edition. Geneva: WHO, 2007;21.
  • Seri K., Sanai K., Kurashima K., Imamura Y., Akita H. (R)-ACX is a novel sufonylurea compound with potent, quick and short-lasting hypoglycemic activity. Eur J Pharmacol 2000;389:253-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Malaisse WJ Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat Endocrinol 2003;2:401-14.[CrossRef][Medline] [Order article via Infotrieve]
  • Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998;15:297-303.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care 1998;21:1052-7.[Abstract]
  • Ball AJ, McCluskey JT, Flatt PR, McClenaghan NH Chronic exposure to tolbutamide and glibenclamide impairs insulin secretion but not transcription of K(ATP) channel components. Pharmacol Res 2004;50:41-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000,108(S6a):15S-22S.
  • NICE. Diabetes - type 2 (update). Type 2 diabetes: the management of type 2 diabetes (update). London: National Institute for Health and Clinical Excellence, 2008. http://www.nice.org.uk/nicemedia/pdf/CG66. (Accessed 01.10.08) diabetesfullguideline.pdf
  • Hill NR, Matthews DR Pioglitazone and metformin. Drugs Today (Barc) 2007;43:443-54.[CrossRef][Medline] [Order article via Infotrieve]
  • Glucophage Summary of Product Characteristics. Feltham: Merck Serono, 2005.
  • Horton ES, Whitehouse F., Ghazzi MN, Venable TC, Whitcomb RW Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group. Diabetes Care 1998;21:1462-9.[Abstract]
  • Bayraktar M., Van Thiel DH, Adalar N. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients. Diabetes Care 1996;19:252-4.[Abstract]
  • Gutniak M., Orskov C., Holst JJ, Ahrén B., Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992;326:1316-22.[Abstract]
  • Baggio LL, Drucker DJ Biology of incretins: GLP-1 and GIP. Gastroenterol 2007;132:2131-57.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nauck MA, Kleine N., rskov C., et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Tourrel C., Bailbe D., Lacorne M., Meile MJ, Kergoat M., Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 2002;51:1443-52.[Abstract/Free Full Text]
  • Toft-Nielsen MB, Damholt MB, Madsbad S. et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86:3717-23.[Abstract/Free Full Text]
  • Lindgren O., Sorhede Winzell M., Deacon C., Ahren B. Diurnal variation in the incretin response to a meal challenge in humans. Diabetologia 2008;51:S2-47.
  • Zander M., Madsbad S., Madsen JL, Holst JJ Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Deacon CF Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 2007;9:S23-31.
  • Fineman MS, Bicsak TA, Shen LZ et al. Effect on glycemic control of exenatide (synthetic exenatide-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003;26:2370-7.[Abstract/Free Full Text]
  • Kendall DM, Riddle MC, Rosenstock J. et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91.[Abstract/Free Full Text]
  • Buse JB, Henry RR, Han J., Kim DD, Fineman MS, Baron AD Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35.[Abstract/Free Full Text]
  • DeFronzo RA, Ratner RE, Han J., Kim DD, Fineman MS, Baron AD Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100.[Abstract/Free Full Text]
  • Garber A., Henry R., Ratner R. et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2008;(In press).
  • Nauck M., Frid A., Hermansen K. et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). Diabetes Care 2008;(In press).
  • Harder H., Nielson L., Thi TD, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-hour energy expenditure in patients with type 2 diabetes. Diabetes Care 2004;27:1915-21.[Abstract/Free Full Text]
  • Holst JJ, Deacon CF Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998;47:1663-70.[Abstract]
  • Lambeir AM, Durinx C., Scharpe S. et al. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209-94.[Web of Science][Medline] [Order article via Infotrieve]
  • Deacon CF, Ahrén B., Holst JJ Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? Exp Opin Investig Drugs 2004;13:1091-102.[CrossRef]
  • He YL, Wang Y., Bullock JM et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol 2007;47:633-41.[Abstract/Free Full Text]
  • Balas B., Baig MR, Watson C. et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007;92:1249-55.[Abstract/Free Full Text]
  • Garber AJ, Foley JE Banerji MA et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab; 2008;10:1047-56.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hermansen K., Kipnes M., Luo E., Fanurik D., Khatami H., Stein P. Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733-45.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Fonseca V., Schweizer A., Albrecht D. et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50:1148-55.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • McClenaghan NH, Flatt PR, Ball AJ Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinide. J Endocrinol 2006;190:889-6.[Abstract/Free Full Text]
  • Galvus summary of product characteristics. Camberley: Novartis Pharmaceuticals, 2008.
  • Januvia summary of product characteristics. Hoddesdon: Merck Sharp & Dohme, 2008.
  • Fehmann H., Göke R., Göke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocrinol Rev 1995;16:390-10.[Abstract/Free Full Text]
  • Dunning BE, Foley J., Ahren B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 2005;48:1700-15.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Doyle ME, Egan JM Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007;113:546-93.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gutniak MK, Juntti-Berggren L., Hellström PM, Guenifi A., Holst JJ, Efendic S. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care 1996;19:857-63.[Abstract]
  • de Heer J., Holst JJ Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes 2007;56:438-43.[Abstract/Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 9, No. 2, 44-52 (2009)
DOI: 10.1177/1474651408101961
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Irwin, N.
Right arrow Articles by Flatt, P. R
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?